BAYERI1 Stock Overview
Bayer S.A. (Peru) engages in the pharmaceuticals, consumer health, and crop science businesses in Peru.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 1/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Bayer S.A. (Peru) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | S/19.00 |
52 Week High | S/20.10 |
52 Week Low | S/14.50 |
Beta | 0.10 |
1 Month Change | -5.47% |
3 Month Change | 34.75% |
1 Year Change | 34.75% |
3 Year Change | 34.75% |
5 Year Change | 35.71% |
Change since IPO | 295.01% |
Recent News & Updates
Recent updates
Shareholder Returns
BAYERI1 | PE Pharmaceuticals | PE Market | |
---|---|---|---|
7D | -5.5% | 2.0% | 0.4% |
1Y | 34.8% | -15.4% | 10.4% |
Return vs Industry: BAYERI1 exceeded the PE Pharmaceuticals industry which returned -15.4% over the past year.
Return vs Market: BAYERI1 exceeded the PE Market which returned 10.4% over the past year.
Price Volatility
BAYERI1 volatility | |
---|---|
BAYERI1 Average Weekly Movement | 11.1% |
Pharmaceuticals Industry Average Movement | 5.5% |
Market Average Movement | 3.6% |
10% most volatile stocks in PE Market | 7.3% |
10% least volatile stocks in PE Market | 0.7% |
Stable Share Price: BAYERI1's share price has been volatile over the past 3 months.
Volatility Over Time: BAYERI1's weekly volatility has increased from 6% to 11% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1947 | n/a | Heiko Klaus Mussmann | www.bayer.com/es/co/andina-ycac-home |
Bayer S.A. (Peru) engages in the pharmaceuticals, consumer health, and crop science businesses in Peru. It operates through three segments: Cropscience, Pharmaceutical, and Consumer Health. The Cropscience segment offers commercialized products, such as pesticides, fertilizers, seeds, and other general products for agricultural sector.
Bayer S.A. (Peru) Fundamentals Summary
BAYERI1 fundamental statistics | |
---|---|
Market cap | S/279.75m |
Earnings (TTM) | S/12.04m |
Revenue (TTM) | S/337.51m |
23.2x
P/E Ratio0.8x
P/S RatioIs BAYERI1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BAYERI1 income statement (TTM) | |
---|---|
Revenue | S/337.51m |
Cost of Revenue | S/237.03m |
Gross Profit | S/100.48m |
Other Expenses | S/88.44m |
Earnings | S/12.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.82 |
Gross Margin | 29.77% |
Net Profit Margin | 3.57% |
Debt/Equity Ratio | 0% |
How did BAYERI1 perform over the long term?
See historical performance and comparison